Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edesa Biotech Inc (EDSA)

Edesa Biotech Inc (EDSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Edesa Biotech Reports Fiscal Year 2025 Results

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4760 (-0.27%)
Interest Rate Decisions Due on Both Sides of Border Next Week

Monday U.S. Featured Earnings Oracle Corp. (NYSE:ORCL) (Q2) EPS for $1.29, compared ...

YEXT : 8.41 (+0.90%)
AVGO : 341.00 (+0.38%)
JOUT : 43.87 (-0.20%)
ORCL : 197.67 (+2.97%)
EDSA : 1.4760 (-0.27%)
TOL : 139.74 (-0.04%)
CIEN : 232.24 (+0.82%)
COST : 850.40 (-0.61%)
FERG : 229.30 (+0.20%)
AZO : 3,413.53 (+0.62%)
ADBE : 358.29 (+0.68%)
SNPS : 480.21 (+3.55%)
Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4760 (-0.27%)
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Study met primary and secondary endpoints Paridiprubart demonstrated a relative reduction in the risk of death of 25% Treatment provided patients with clinically meaningful improvement in survival...

EDSA : 1.4760 (-0.27%)
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases,...

EDSA : 1.4760 (-0.27%)
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

EDSA : 1.4760 (-0.27%)
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

EDSA : 1.4760 (-0.27%)
Edesa Biotech Announces Chief Financial Officer Transition

EDSA : 1.4760 (-0.27%)
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

EDSA : 1.4760 (-0.27%)
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

EDSA : 1.4760 (-0.27%)

Barchart Exclusives

As Nvidia Acquires SchedMD, Should You Buy, Sell, or Hold NVDA Stock?
Nvidia’s acquisition of SchedMD is strengthening its AI and computing capabilities. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar